NAT2 and tuberculosis: Implementation of pre-treatment NAT2 genotyping in high-risk populations could further enhance the safety of anti-TB therapy by enabling individualized isoniazid dosing, thereby reducing the incidence of severe ADRs and optimizing personalized TB management strategies.